Jennifer Prescott

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

44h-index6.6kcitations124works1.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Telomeres, Telomerase, and Senescence(42), Prostate Cancer Treatment and Research(15), Genetic Associations and Epidemiology(14), Epigenetics and DNA Methylation(13), Genetics, Aging, and Longevity in Model Organisms(13)

Publications120 total

Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma by line of therapy
Future Oncology·2025
A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens.
Journal of Clinical Oncology·2025
Real-World Characteristics, Treatment Patterns, and Outcomes of Patients with Mantle Cell Lymphoma By LOT
Blood·2024· 1 citedOpen Access
Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States
Blood Neoplasia·2024· 6 citedOpen Access
Supplemental Materials from Sex-Specific Association between Family History of Diabetes and Risk of Colorectal Cancer: Two Prospective Cohort Studies
2023Open Access
Supplemental Materials from Sex-Specific Association between Family History of Diabetes and Risk of Colorectal Cancer: Two Prospective Cohort Studies
2023Open Access
Data from Sex-Specific Association between Family History of Diabetes and Risk of Colorectal Cancer: Two Prospective Cohort Studies
2023Open Access
Data from Sex-Specific Association between Family History of Diabetes and Risk of Colorectal Cancer: Two Prospective Cohort Studies
2023Open Access
Supplemental Results from Endometrial Cancer Risk Factors, Hormone Receptors, and Mortality Prediction
2023Open Access
Data from Endometrial Cancer Risk Factors, Hormone Receptors, and Mortality Prediction
2023Open Access
Data from Endometrial Cancer Risk Factors, Hormone Receptors, and Mortality Prediction
2023Open Access
Supplemental Materials and Methods from Endometrial Cancer Risk Factors, Hormone Receptors, and Mortality Prediction
2023Open Access
Supplemental Materials and Methods from Endometrial Cancer Risk Factors, Hormone Receptors, and Mortality Prediction
2023Open Access
Supplemental Results from Endometrial Cancer Risk Factors, Hormone Receptors, and Mortality Prediction
2023Open Access
Supplementary Materials, Figures 1 - 3, Tables 1 - 4, 6 - 8 from The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease
2023Open Access
Supplementary Table 5 from The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease
2023Open Access
Supplementary Data 1-4 from Control of Androgen Receptor Signaling in Prostate Cancer by the Cochaperone Small Glutamine–Rich Tetratricopeptide Repeat Containing Protein α
2023Open Access
Data from The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease
2023Open Access
Data from Control of Androgen Receptor Signaling in Prostate Cancer by the Cochaperone Small Glutamine–Rich Tetratricopeptide Repeat Containing Protein α
2023Open Access
Data from Control of Androgen Receptor Signaling in Prostate Cancer by the Cochaperone Small Glutamine–Rich Tetratricopeptide Repeat Containing Protein α
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Immaculata De Vivo(39), Peter Kraft(15), Montserrat García‐Closas(10), Stephen J. Chanock(9), David J. Hunter(9), Xiaolin Liang(8), Mia M. Gaudet(8), Louise A. Brinton(8), Veronica Wendy Setiawan(7), Hannah Yang(7), Sara H. Olson(7), Jolanta Lissowska(7), Christine M. Friedenreich(7), Jennifer A. Doherty(7), Linda S. Cook(7), Xiao‐Ou Shu(6), Harvey A. Risch(6), Anthony M. Magliocco(6), Lingeng Lu(6), Chu Chen(6)